New approaches in treatment of B-cell chronic lymphocytic leukemia

Cancer Therapy

Volumn 7, Issue ISSUE A, 2009, Pages 163-173

  Stram, Mariusz ^a   Tabarkiewicz, Jacek ^a   Hus, Iwona ^a   Roliński, Jacek ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Chronic lymphocytic leukemia; Dendritic cells; Immunotherapy; Monoclonal antibodies

Indexed keywords

ALEMTUZUMAB; ARSENIC TRIOXIDE; BENDAMUSTINE; BETA 2 MICROGLOBULIN; CD38 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DOXORUBICIN; EPRATUZUMAB; ETODOLAC; FLAVOPIRIDOL; FLUDARABINE; GALIXIMAB; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOMODULATING AGENT; LACTATE DEHYDROGENASE; LENALIDOMIDE; LUMILIXIMAB; OBLIMERSEN; OFATUMUMAB; PREDNISONE; PROTEIN KINASE ZAP 70; RITUXIMAB; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DEPENDENT LYMPHOCYTOTOXICITY; ANTIGEN BINDING; APOPTOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LEUKEMIA; BETA 2 MICROGLOBULIN URINE LEVEL; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMPLEMENT DEPENDENT CYTOTOXICITY; DISEASE COURSE; DRUG RESPONSE; ENZYME INHIBITION; GENE MUTATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHADENOPATHY; NEUROLOGIC DISEASE; NONHUMAN; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; REMISSION; REVIEW; SEDATION; SIDE EFFECT; SURVIVAL TIME; TREATMENT INDICATION;

EID: 69949112819     PISSN: 15439135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Alfarano A, Indraccolo S, Circosta P, Minuzzo S, Vallario A, Zamarchi R, Fregonese A, Calderazzo F, Faldella A, Aragno M, Camaschella C, Amadori A, Caligaris-Cappio F (1999) An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia. Blood 93, 2327-2335.
2. Banerji V, Johnston JB, Seftel MD (2007) The role of hematopoietic stem cell transplantation in Chronic Lymphocytic Leukemia. Transfus Apher Sci 37, 57-62.
3. Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, Foster A, Havlik-Cooper D, Grilley B, Gee A, Baker K, Carrum G, Rice L, Andreeff M, Popat U, Brenner M (2005) Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res 11, 6916-23.
4. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48, 198-206.
5. Bosch F, Villamor N (2003) ZAP-70 expression in chronic lymphocytic leukaemia: a new parameter for an old disease. Haematologica 88, 724-725.
6. Abbott BL (2006) Chronic Lymphocytic Leukemia: Recent Advances in Diagnosis and Treatment; The Oncologist 11, 21-30.
7. Carnahan J, Stein R, Qu Z, Hess K, Czesano A, Hansen H, Goldenberg D (2007) Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Molecular Immunology 44, 1331-1341.
8. Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS (2006) Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 24, 5343-5349.
9. Chanan-Khan A, Miller KC, Takeshita K, Koryzna A, Donohue K, Bernstein ZP, Mohr A, Klippenstein D, Wallace P, Zeldis JB, Berger C, Czuczman MS (2005) Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 106, 3348-3352.
10. Chanan-Khan A, Porter CW (2006) Immunomodulating drugs for chronic lymphocytic leukaemia. Lancet Oncol 7, 480-488.
11. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR (1996) National Cancer Institute-Sponsored Working Group Guideline For Chronic Lymphocytic Leukemia: Revised Guidelines for Diagnosis and Treatment. Blood 87, 4990-4997.
12. Christian BA,. Grever MR, Byrd J, Lin TS (2007) Flavopiridol in the treatment of chronic lymphocytic leukemia. Current Opinion in Oncology 19, 573-578.
13. Chu P, Scales L, Zou A (2003) Mechanism of IDEC-152-induced apoptosis in chronic lymphocytic leukemia B cells. Proc Am Assoc Cancer Res (2nd ed), 126-127.
14. Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MH, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, Walewski J, Flensburg M, Petersen J, Robak T (2008) Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 111, 1094-100.
15. Constantine S. Tam, Susan O'Brien, William Wierda, Hagop Kantarjian, Sijin Wen, Kim-Anh Do, Deborah A. Thomas, Jorge Cortes, Susan Lerner, and Michael J. Keating (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimenas initial therapy of chronic lymphocytic leukemia. Blood 112, 975-980.
16. Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T, Vegna ML, Guglielmi C, Mancini F, Giuliacci S, Sacchi A, Mandelli F, Foa R (1998) p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 91, 4342-4349.
17. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, Marcé S, López-Guillermo A, Campo E, Montserrat E (2003) ZAP-70 expression as a surrogate for Immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348, 1764-1775.
18. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N (1999) Ig V gene mutation status and CD38 expression as a novel prognostic indicators in chronic lymphoctic leukemia. Blood 94, 1840-1847.
19. Dearden C (2002) Monoclonal antibody therapy of haematological malignancies. Bio Drugs 16, 283-301.
20. Del Poeta G, Del Principe M, Buccisano F, Maurillo L, Apelli G, Luciano F, Pio Perrotti A, Degan M, Venditti A, De Fabritiis P, Gattei V, Amadori S (2008) Consolidation and Maintenance Immunotherapy With Rituximab Improve Clinical Outcome in Patients With B-cell Chronic Lymphocytic Leukemia. Cancer 112, 119-128
21. Del Poeta G, Maurillo L, Venditti A, Buccisano F, Epiceno AM, Capelli G, Tamburini A, Suppo G, Battaglia A, Del Principe MI, Del Moro B, Masi M, Amadori S (2001) Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 98, 2633-2639.
22. Dighiero G (2005) CLL Biology and Prognosis. Hematology Am Soc Hematol Educ Program 278-284.
23. Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, Leporrier M, Jaubert J, Lepeu G, Dreyfus B, Binet JL, Travade P (1998) Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 338, 1506-1514.
24. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343, 1910-1916.
25. Dreger P, Brand R, Mulligan D (2005) Reduced intensity conditioning lowers treatment related mortality of allogenic stem cell transplantation for chronic lymphocytic leukemia: a population matches analysis. Leukemia 19:1029-1033.
26. Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J, Wiktor-Jedrzejczak W, Niederwieser D, Hallek M and E Montserrat E, on behalf of the Chronic Leukemia Working Party of the EBMT (2007) Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia:the EBMT transplant consensus. Leukemia 21, 12-17.
27. Eichrost BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S, Jager U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Dohner H, Brittinger G, Emmerich B, Hallek M German CLL Study Group (2006) Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107(3), 885-891.
28. Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P, Schinkothe T, Stutzer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A Hallek M, Engert A (2005) Fludarabine in combination in patients with relapsed or refractory a B-cell chronic lymphocyticleukemia: results of phase II trial. J Clin Oncol 23 (28), 7024-7031.
29. Esteve J, Villamor N, Colomer D, Cervantes F, Campo E, Carreras E, Montserrat E (2001) Stem cell Transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia 15, 445-451.
30. Flinn IW, Berdeja JG (2004) The initial management of patients with chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 170-175.
31. French Cooperative Group on Chronic Lymphocytic Leukemia (1990) A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. Blood 75, 1422-1425.
32. Furman RR, Leonard JP, Allen SL, Coleman M, Rosenthal T, Gabrilove JL (2005) Thalidomide alone or in combination with fludarbabine are effective treatments for patients with fludarabine-relapsed and refractory CLL. J Clin Oncol, ASCO Annual Meeting Proceedings 23, 16S, Part I of II, 6640.
33. Gilleece MH, Dexter TM (1993) Effect of Campath-lH antibody on human hematopoietic progenitors in vitro. Blood 82, 807-812.
34. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D (1998) Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 51, 364-369.
35. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95, 3900-3908.
36. Grever MR, Kopecky KJ, Coltman CA, Files JC, Greenberg BR, Hutton JJ, Talley R, Von Hoff DD, Balcerzak SP (1988) Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 30, 457-459.
37. Grever MR, Lucas DM, Johnson AJ, Byrd JC (2007) Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol. 20(3), 545-556.
38. Gribben JG American Society for Blood and Marrow Transplantation (2009) Stem Cell Transplantation in Chronic Lymphocytic Leukemia Biol Blood Marrow Transplant 15, 1553-1558.
39. Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC, Freedman AS, Mauch P, Schlossman R, Sequist LV, Soiffer RJ, Marshall B, Neuberg D, Ritz J, Nadler LM (2005) Autologous and allogeneic stem cell transplantation for poor risk chronic lymphocytic leukemia. Blood 106, 4389-4396.
40. Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA (2003) Network Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 21, 1746-1751.
41. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111, 5446-5456.
42. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ International Workshop on Chronic Lymphocytic Leukemia (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111, 5446-5456.
43. Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, Hallett W, Tsou HR, Upeslacis J, Shochat D, Mountain A, Flowers DA, Bernstein I (2002) Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 13, 47-58.
44. Hamblin TJ, Davis Z, Gardiner A, Oscier DG & Stevenson FK (1999) Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848-1854.
45. Han T, Ezdini EZ, Shimaoka K, Desai DV (1973) Chlorambucil versus combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer 31, 502-508.
46. Herishanu Y., Polliack A (2005) Chronic lymphocytic leukemia: A review of some new aspects of the biology, factors influencing prognosis and therapeutic options. Transfusion and Apheresis Science 32, 85-97.
47. Hus I, Kawiak J, Tabarkiewicz J, Radej S, Hoser G, Bojarska-Junak A, Schmitt M, Giannopoulos K, Dmoszynska A, Rolinski J (2008) Immunotherapy with irradiated autologous leukemic cells in patients with B-CLL in early stages Oncology Reports 2008 20, 443-451.
48. Hus I, Roliński J, Tabarkiewicz J, Wojas K, Bojarska-Junak A, Greiner J, Giannopoulos K, Dmoszynska A, Schmitt M (2005) Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 19, 1621-1627.
49. Hus I, Schmitt M, Tabarkiewicz J, Radej S, Wojas K, Bojarska-Junak A, Schmitt A, Giannopoulos K, Dmoszynska A, Rolinski J (2008) Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia 22, 1007-1017.
50. Hus I., Podhorecka M., Bojarska-Junak A., Roliński J., Schmidt M., Sieklucka M., Wasik-Szczepanek E., Dmoszyńska A. (2006); The clinical significance of ZAP-70 and CD38 expression In B-cell chronic lymphocytic leukemia; Annals of Oncology 17, 683-690
51. Jensen M, Engert A, Weissinger F, Knauf W, Kimby E, Poynton Ch, Anton Oliff I, J. Rummel M and Österborg A (2008) Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia. Inwest New Drugs 26, 139-149
52. Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S (2007) Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res 13, 4448-4455.
53. Johnson S, Smith AG, Loffler H, Osby E, Juliusson G, Emmerich B, Wyld PJ, Hiddemann W (1996) Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. The French Cooperative Group on CLL. Lancet 347, 1432-1438.
54. Kay NE, Jelinek DF, Dewald GW (2002) Progression events in B-chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 197-213.
55. Keating M (2007) Chemoimmunotherapy of chronic lymphocytic leukemia Best Practice & Research Clinical Haematology 20, 3479-3498.
56. Keating M, O'Brien S (2000) High-dose rituximab therapy in chronic lymphocytic leukemia. Semin Oncol Suppl 12, 86-90.
57. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23, 4079-4088.
58. Kharfan-Dabaja MA, Anasetti C, Santos ES (2007) Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept. Biol Blood Marrow Transplant 13, 373-385.
59. Kitada S, Zapata JM, Andreeff M, Reed JC (2000) Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine downregulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 96, 393-397.
60. Lens D, Dyer MJ, Garcia-Marco JM, De Schouwer PJ, Hamoudi RA, Jones D, Farahat N, Matutes E, Catovsky D (1997) p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis. Br J Haematol 99, 848-857.
61. Leporrier M, Chevre S, Cazin B, Boudjerra N, Feugier P, Desablens B, Rapp MJ, Jaubert J, Autrand C, Divine M, Dreyfus B, Maloum K, Travade P, Dighiero G, Binet JL, Chastang C French Cooperative Group on Chronic lymphocytic Leukemia (2001) Randomized comparision of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 98, 2319-2325.
62. Lin TS, Stock W, Lucas MS (2002) A phase I dose escalation study of apolizumab (Hu1D10) using a stepped up dosing schedule in patients with chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL). Blood 100, 3167.
63. Linet MS (1988) Chronic lymphocytic leukemia. Polliack A Catovsky D, editors. The epidemiology of chronic lymphocytic leukemia. Chur: Harwood Academic Publishers, 11-32.
64. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, Mollgard L, Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A (2002) Phhase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100, 768-773.
65. Lundin J, Osterborg A (2004) Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia. Semin Hematol 41, 234-245.
66. Maloney DG, Smith B, Rose A (2002) Rituximab: mechanism of action and resistance. Semin Oncol 29, 2-9.
67. McConkey DJ (1998) Biochemical determinants of apoptosis and necrosis. Toxicol Lett 99, 157-168.
68. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16, 2825-2833.
69. Merkel O, Heuder C, Asslaber D, Hamacher F, Tinhofer I, Holler C, Stocher M, Prokesch A, Papak C, Scheideler M, Trajanoski Z, Greol R (2008) Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13. J Mol Med 86, 541-552.
70. Messmer B, Damle RN, Allen SL, Rai KR, Ferrarini M, Kipps TJ (2003) Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 153-175.
71. Molica S (1991) Progression and survival studies in early chronic lymphocytic leukemia. Blood 78, 895-899.
72. Molica S (2007) Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm. Leuk Lymphoma 48, 866-869.
73. Mone AP, Huang P, Pelicano H, Cheney CM, Green JM, Tso JY, Johnson AJ, Jefferson S, Lin TS, Byrd JC (2004) Alemtuzumab induces cell death in human chronic lymphocytic leukemia cells through lipid-raft dependent mechanism. Blood 104, 1846-1854.
74. Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E (2005) Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica 90, 391-399.
75. Montserrat E, Gine E, Moreno C, Esteve J (2007) The role of stem-cell transplantation in chronic lymphocytic leukemia risk-adapted therapy. Best Practice & Research Clinical Haematology 20, 529-543.
76. Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A, Tighe J, Oscier D, Fegan C, Rawstron A, Hillmen P (2005) Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 23, 2971-2979.
77. Obermann E, Went P, Tzankov A, Pileri S, Hofstaedter F, Marienhagen J, Stoehr R, Dirnhofer S (2007) Cell cycle phase distribution analysis in chronic lymphocytic leukaemia: a significant number of cells reside in early G1-phase. Journal of Clinical Pathology 60, 794-797.
78. Opezzo P, Vasconcelos Y, Settegrana C, Jeannel D, Vuillier F, Legarff-Tavernier M, Kimura EY, Bechet S, Dumas G, Brissard M, Merle-Beral H, Yamamoto M, Dighiero G, Davi F French Cooperative Group on CLL (2005) The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 106, 650-657.
79. Oscier DG, Thompsett A, Zhu D, Stevenson FK (1997) Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood 89, 4153-4160.
80. Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15, 1567-1574.
81. Palma M, Kokhaei P, Lundin J, Choudhury A, Mellstedt H, Osterborg A (2006) The biology and treatment of chronic lymphocytic leukemia. Annals of Oncology 17, 144-154.
82. Penesha S, Milligan DW (2005) Stem cell transplantation for chronic lymphocytic leukemia. Br J Haematol 128, 145-152.
83. Poole J, Meng J, Reff M, Spellman M, Rosenwasser L (2005) Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol 116, 780-788.
84. Rai KR, Dohner H, Keating MJ, Montserrat E (2001) Chronic lymphocytic leukemia: case-based session. Hematology Am Soc Hematol Educ Program 140-156.
85. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J, Threatte GA, Larson RA, Cheson BD, Schiffer CA (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 14, 1750-1757.
86. Rai KR, Sawitsky A, Croncite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46, 219-234.
87. Ritgen M, Stilgenbauer S, von Neuhoff N, Humpe A, Brüggemann M, Pott C, Raff T, Kröber A, Bunjes D, Schlenk R, Schmitz N, Döhner H, Kneba M, Dreger P (2004) Graft-versus-leukemia activity May overcome therapeutic resistance of chronic lymphocytic leukemia with unmutatedimmunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 104, 2600-2602.
88. Robak T (2007) Recent progress in the management of chronic lymphocytic leukemia. Cancer Tretment Reviews 33, 710-728.
89. Robak T, Bloński JZ, Kasznicki M, Blasinska-Morawiec M, Krykowski E, Dmoszyńska A, Mrugała-Śpiewak H, Skotnicki AB, Nowak W, Konopka L, Ceglarek B, Maj S, Dwilewicz-Trojaczek J, Hellmann A, Urasinski I, Zdziarska B, Kotlarek-Haus S, Potoczek S, Grieb P (2000) Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 96, 2723-2729.
90. Robak T, Kasznicki M (2002) Alkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukemia. Leukemia 16, 1015-1027.
91. Robak T, Sergey I, Moisee IS, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, Afanasiev VB, Larratt L, Geisler Ch, Montillo M, Ganly P, Dartigeas C, Rosta A, Janssens A, Mendila M, Maurer J and Wenger MK (2008) Rituximab, Fludarabine, and Cyclophosphamide (RFC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial. ASH Annual Meeting Abstracts Blood 112: Abstract 1
92. Rozman C, Montserrat E (1995) Chronic lymphocytic leukemia, N Eng J Med 333, 1052-1057.
93. Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, Aulitzky WE, Hensel M, Herold M, Huhn D, Hallek M, Diehl V, Engert A German CLL Study Group (2002) Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 100, 3115-3120.
94. Sgambati M, Linet MS, Devesa S (2003) Chronic lymphoid leukemias. In: Cheson BD, editor. Chronic lymphoid leukemias. 2nd ed. New York: M. Dekker, 33-62.
95. Shanafelt TD, Geyer SM, Kay NE (2004) Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 103, 1202-1210.
96. Spaner DE, Hammond C, Mena J, Foden C, Deabreu A (2005) A phase I/ II trial of oxidized autologous tumor vaccines during the "watch and wait" phase of chronic lymphocytic leukemia. Cancer Immunol Immunother 54, 635-46.
97. Stein R, Qu Z, Cardillo T, Chen S, Rosario A,. Horak I, Hansen H, Goldenberg D (2004) Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 104, 3705-3711.
98. Stilgenbauer S, Dohner H (2002) Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 347, 452-453.
99. O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR (2007) Randomized Phase III Trial of Fludarabine PlusCyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. J Clin Oncol 25, 1114-1120.
100. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren PW, Hack CE, Dechant M, Valerius T, van de Winkel JG, Glennie MJ (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104, 1793-1800.
101. Tong X, Georgakis GV, Long L, O'Brien S, Younes A, Luqman M (2005) In Vitro Activity of a Novel Fully Human Anti- CD40 Antibody CHIR-12.12 in Chronic Lymphocytic Leukemia: Blockade of CD40 Activation and Induction of ADCC. ASH Annual Meeting Abstracts. Blood 106, 2504.
102. Van't Veer MB, Brooijmans AM, Langerak AW, Verhaaf B, Goudswaard CS, Graveland WJ, an Lom K, Valk PJ (2006) The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. Haematologica 1, 56-63.
103. Vasconcelos Y, Davi F, Levy V, Oppezzo P, Magnac C, Michel A, Yamamoto M, Pritsch O, Merle-Béral H, Maloum K, Ajchenbaum-Cymbalista F, Dighiero G (2003) Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. Journal of Clinical Oncology 21, 3928-3932.
104. Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G Eichhorst B, Busch R, Diem H, Englert A, Stilgenbauer S, Dohner H, Kneba M, Eichhorst B, Busch R, Study Group (GCLLSG) (2004) Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 18, 1093-1101.
105. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ (2000) CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96, 2917-2924.
106. Knauf WU, Lissichkov T, Aldaoud A, Herbrecht R, Liberati AM, Loscertales J, Juliusson G, Dittrich Ch, Merkle K (2007) Bendamustine Versus Chlorambucil in Treatment-Naive Patients with B-Cell Chronic Lymphocytic Leukemia (BCLL): Results of an International Phase III Study. Blood (ASH Annual Meeting Abstracts) 110, Abstract 2043.
107. Zent CS, Kay NE (2004) Update on monoclonal antibody therapy in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2, 107-113.